Integración del ascorbato de sodio intravenoso y de la medicina biorreguladora de sistemas como soporte durante el tratamiento de neoplasias sincrónicas de mama y endometrio: reporte de un caso

AbstractBackground: Evidence regarding intravenous ascorbate and systems bioregulatory medicine (SBRM) as oncological support is limited and heterogeneous. Its incorporation during the treatment of two synchronous primary neoplasms is described.Clinical Case: A 74-year-old female with triple-negative carcinoma of the right breast, initially cT2N0M0, and serous carcinoma of the endometrium. She received four neoadjuvant cycles of doxorubicin and cyclophosphamide, surgery for both neoplasms, and six adjuvant cycles of paclitaxel and carboplatin, alongside conventional support, intravenous sodium ascorbate, and SBRM preparations.Results: She completed the ten planned cycles with no documented dose reductions, maintaining an ECOG score of 0 and a Karnofsky performance status between 90% and 100%. Grade 4 neutropenia was recorded before the third neoadjuvant cycle, with 290 neutrophils/µL and subsequent recovery, with no documented febrile neutropenia. Asthenia, anemia, and peripheral neuropathy were also described. The largest diameter of the breast lesion decreased from 33 to 12 mm, and the endometrial thickness changed from 20 to 6 mm. Histopathology confirmed residual disease in both sites. At the last clinical follow-up, performed on October 10, 2026, no evidence of tumor activity or active toxicities was recorded.Conclusion: The complementary support coexisted with treatment completion and functional preservation. The single-case design and concomitant interventions prevent attributing the tumor response, toxicity reduction, or therapeutic continuity to it. Prospective evaluations are required to establish its specific contribution.